🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

One Part of Australia’s Economy Is Booming: Illegal Drugs

Published 11/12/2018, 03:02 pm
Updated 11/12/2018, 04:14 pm
© Bloomberg. Brightly coloured pharmaceutical medication, including antibiotics, paracetamol, Ibuprofen and cold relief tablets, manufactured by a variety of companies sit in this arranged photograph in London, U.K., on Friday, April 27, 2018. Pharmaceutical companies may see approval times cut to 14 months vs. 19 and about $370 million of sales brought forward per antibiotic after global regulators aligned rules to combat bacterial resistance.

(Bloomberg) -- As the Reserve Bank frets about Australia’s slowing levels of consumption, it’s found one area that appears to be holding up well.

Australians spent A$13.5 billion ($9.7 billion) on illicit drugs in the year through August 2017, the central bank estimates, with methamphetamine and cannabis accounting for over 70 percent of purchases. That’s among findings of a research paper released Tuesday exploring usage of the nation’s bank notes, of which it reckons almost 2 percent is for illegal drug deals.

“Excluding cannabis, methamphetamine -- also known as meth or ice -- is the most used illicit drug in Australia by weight, followed by cocaine, MDMA -- also known as ecstasy -- and then heroin,” the report said, citing analysis of wastewater that’s used to measure the population’s drug consumption.

Researchers calculated that the stock of actual notes used in drug purchases -- after taking into account how often the same note tends to change hands -- was a little over A$1 billion.

To estimate the value of cash used to pay for illegal drugs, the RBA paper assumed:

  • All drug purchases were made with bank notes, as research shows most users still buy face-to-face;
  • To account for drugs typically being cut with other substances, the RBA paper divided volumes by average purity levels; and
  • The researchers incorporated estimates of the drugs’ street value

As for the denominations of notes used in such activities, law enforcement agencies suggest the A$50 bill tends to be the favored form of payment.

© Bloomberg. Brightly coloured pharmaceutical medication, including antibiotics, paracetamol, Ibuprofen and cold relief tablets, manufactured by a variety of companies sit in this arranged photograph in London, U.K., on Friday, April 27, 2018. Pharmaceutical companies may see approval times cut to 14 months vs. 19 and about $370 million of sales brought forward per antibiotic after global regulators aligned rules to combat bacterial resistance.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.